Ethiopia
Tuberculosis profile
| High TB burden | High HIV burden | High MDR-TB burden |
Population  2013 94 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 30 (16–47) 32 (17–50)
Mortality (HIV+TB only) 5.6 (3.6–8) 5.9 (3.8–8.5)
Prevalence  (includes HIV+TB) 200 (160–240) 211 (170–257)
Incidence  (includes HIV+TB) 210 (180–260) 224 (188–276)
Incidence (HIV+TB only) 22 (19–32) 24 (21–33)
Case detection, all forms (%) 62 (51–74)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.6 (0.9–2.8) 12 (5.6–21)
MDR-TB cases among notified pulmonary
TB cases
1 400 (800–2 500)   (–)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 43 860    
Pulmonary, clinically diagnosed 45 464    
Extrapulmonary 42 353    
       
Total new and relapse 131 677    
Previously treated, excluding relapses      
Total cases notified 131 677    
Among 131 677 new cases:
21 317 (16%) cases aged under 15 years; male:female ratio: 1.2
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 212 (<1%) 1 095 3 071
Laboratory-confirmed RR-/MDR-TB cases     558
Patients started on MDR-TB treatment     413
TB/HIV 2013 Number (%)
TB patients with known HIV status 93 356 (71)
HIV-positive TB patients 10 374 (11)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 7 055 (68)
HIV-positive people screened for TB 324 674  
HIV-positive people provided with IPT 15 424  
Treatment success rate (%)
New cases registered in 2012 91
Previously treated cases registered in 2012 43
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 72
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 2.2
Culture (per 5 million population) 0.4
Drug susceptibility testing (per 5 million population) 0.4
Sites performing Xpert MTB/RIF 23
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 94
% Funded domestically 7%
% Funded internationally 30%
% Unfunded 63%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-31 Data: www.who.int/tb/data